Drug intelligence / Profile preview

TMC558445

Development stage: Phase 1
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

TMC558445 is an investigational **small molecule cytochrome P450 (CYP) inhibitor** developed for use as a standalone pharmacokinetic booster, particularly to increase the plasma levels of other antiretroviral agents such as the HIV protease inhibitor TMC310911 and possibly Darunavir. It has been studied in healthy volunteers for its safety, tolerability, and pharmacokinetic properties, focusing on dosage escalation and its pharmacokinetic enhancing effects. This agent was developed by Tibotec Pharmaceuticals and subsequently associated with Janssen and Janssen Global Services. Its development for HIV infection reached Phase 1 clinical testing but has since been discontinued[1][3][5][7].

Other names: TMC-558445TMC558445TMC 558445

Targets

CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on TMC558445.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMC558445.

Explore the full profile